Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade) [Seeking Alpha]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Seeking Alpha
Partnerships with Janssen and Horizon Therapeutics have been terminated, and several drug candidates have been shelved. Arrowhead's near-term approval shots include plozasiran, olpasiran, and fazirsiran, but they face competition from other companies in their respective markets. Investment Overview Back in 2019 I covered Arrowhead Pharmaceuticals ( NASDAQ: ARWR ), a drug developer focused on RNA-interference therapeutics in a note for Seeking Alpha. The note still provides an accurate overview of Arrowhead's history, from acquiring RNA assets and a manufacturing facility from Swiss Pharma giant Roche ( OTCQX:RHHBY ), to purchasing another Swiss Pharma, Novartis' ( NVS ) RNA-interference portfolio, assets it failed to develop successfully, before two mega-deals were agreed with Californian Pharma giant Amgen ( AMGN ), and Johnson & Johnson ( JNJ ) drug development subsidiary Janssen in 2018, to co-develop a variety of pipeline assets, leading to a surge in the company's valuat
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 ConferencesBusiness Wire
- Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D WebinarsBusiness Wire
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter ResultsBusiness Wire
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney DiseaseBusiness Wire
ARWR
Earnings
- 8/7/23 - Miss
ARWR
Sec Filings
- 4/10/24 - Form SC
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- ARWR's page on the SEC website